Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Authors:
- Lisa A. BeckLBLisa A. Beck
- Diamant ThaçiDTDiamant Thaçi
- Jennifer D. HamiltonJHJennifer D. Hamilton
- Neil M. GrahamNGNeil M. Graham
- Thomas BieberTBThomas Bieber
- Ross RocklinRRRoss Rocklin
- Jeffrey E. MingJMJeffrey E. Ming
- Haobo RenHRHaobo Ren
- Richard KaoRKRichard Kao
- Eric SimpsonESEric Simpson
- Marius ArdeleanuMAMarius Ardeleanu
- Steven P. WeinsteinSWSteven P. Weinstein
Top Cited Papers
Open Access
- 10 July 2014
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (2) , 130-139
Abstract
Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)–mediated inflammation could help in the treatment of related diseases, including atopic dermatitis. We performed randomized, double-blind, placebo-controlled trials involving adults who had moderate-to-severe atopic dermatitis despite treatment with topical glucocorticoids and calcineurin inhibitors. Dupilumab was evaluated as monotherapy in two 4-week trials and in one 12-week trial and in combination with topical glucocorticoids in another 4-week study. End points included the Eczema Area and Severity Index (EASI) score, the investigator's global assessment score, pruritus, safety assessments, serum biomarker levels, and disease transcriptome. In the 4-week monotherapy studies, dupilumab resulted in rapid and dose-dependent improvements in clinical indexes, biomarker levels, and the transcriptome. The results of the 12-week study of dupilumab monotherapy reproduced and extended the 4-week findings: 85% of patients in the dupilumab group, as compared with 35% of those in the placebo group, had a 50% reduction in the EASI score (EASI-50, with higher scores in the EASI indicating greater severity of eczema) (P<0.001); 40% of patients in the dupilumab group, as compared with 7% in the placebo group, had a score of 0 to 1 (indicating clearing or near-clearing of skin lesions) on the investigator's global assessment (P<0.001); and pruritus scores decreased (indicating a reduction in itch) by 55.7% in the dupilumab group versus 15.1% in the placebo group (P<0.001). In the combination study, 100% of the patients in the dupilumab group, as compared with 50% of those who received topical glucocorticoids with placebo injection, met the criterion for EASI-50 (P=0.002), despite the fact that patients who received dupilumab plus glucocorticoids used less than half the amount of topical glucocorticoids used by those who received placebo plus the topical medication (P=0.16). Adverse events, such as skin infection, occurred more frequently with placebo; nasopharyngitis and headache were the most frequent adverse events with dupilumab. Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity. Side-effect profiles were not dose-limiting. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01259323, NCT01385657, NCT01639040, and NCT01548404.)Keywords
This publication has 18 references indexed in Scilit:
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsNew England Journal of Medicine, 2013
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- Guidelines for treatment of atopic eczema (atopic dermatitis) Part IIJournal of the European Academy of Dermatology and Venereology, 2012
- Guidelines for treatment of atopic eczema (atopic dermatitis) Part IJournal of the European Academy of Dermatology and Venereology, 2012
- Epidemiology of atopic dermatitis: a reviewAllergy and Asthma Proceedings, 2012
- Comparative Effectiveness of Topical Calcineurin Inhibitors in Adult Patients with Atopic DermatitisAmerican Journal of Clinical Dermatology, 2012
- Skin Barrier Disruption: A Requirement for Allergen Sensitization?Journal of Investigative Dermatology, 2012
- EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important differenceAllergy, 2011
- Safety, Efficacy, and Dosage of 1% Pimecrolimus Cream for the Treatment of Atopic Dermatitis in Daily PracticeAmerican Journal of Clinical Dermatology, 2006
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001